GlaxoSmithKline has licensed MedImmune’s reverse genetics technology for the development of new vaccine strains to produce non-live human influenza vaccines. Reverse genetics allows manufacturers to avoid working directly with the infectious, circulating pandemic strains, such as H5N1, by generating viruses such as influenza from segments of DNA. “MedImmune is pleased to enter into a fourth agreement to license our reverse genetics technology to manufacturers,” said Jonath...